ResMed Inc. — Earnings

Most recent reported period: FY2025 (Q4) (filed for period ending 2025-12-31) · sourced from SEC EDGAR

Next earnings (estimated): Wed, April 1, 2026 30 days overdue (likely already filed but EDGAR cache cold). Anchored to latest quarter-end + 91 days. Analyst-confirmed dates land in a follow-up wave.
YoY = vs same quarter prior year (seasonality-adjusted)

Recent earnings · last 8 quarters

Quarter endRevenueYoYNet IncomeYoYOp. Margin
2025-12-31$1.42B↑+11.0%$393M↑+13.9%34.6%
2025-09-30$1.34B↑+9.1%$349M↑+11.9%33.4%
2025-06-30$1.35B↑+10.2%$380M↑+29.9%33.7%
2025-03-31$1.29B↑+7.9%$365M↑+21.5%33.0%
2024-12-31$1.28B↑+10.3%$345M↑+65.0%32.5%
2024-09-30$1.22B↑+11.1%$311M↑+41.9%31.6%
2024-06-30$1.22B↑+9.0%$292M↑+27.2%31.2%
2024-03-31$1.20B↑+7.2%$300M↑+29.2%31.3%

Analyst consensus estimates (EPS / Revenue) and implied move from options will land in a follow-up wave. For now, YoY-vs-prior-year-quarter is the surprise proxy.

Last earnings · FY2025 (Q4)

Revenue
$1.42B
↑+11.0% +$141M YoY
Net Income
$393M
↑+13.9% +$48M YoY

Earnings surprise · last 8 quarters

YoY % change · proxy for analyst surprise until estimates land

EPS history · last 10 fiscal years

diluted, GAAP, annual

Note: EPS reflects WEIGHTED-AVERAGE diluted shares for each fiscal year. Pre-stock- split values can blow up the early bars if SEC's XBRL data isn't split-adjusted — flagged as a known limitation; cumulative split-adjustment is a follow-up.

Margin trends · 66 quarters

margin trajectory tells the operating-leverage story
Gross Margin↑+3.2pts
61.8%
Operating Margin↑+2.0pts
34.6%
Net Margin↑+0.7pts
27.6%

Go deeper